Anthem Biosciences IPO Listing: Share Price, Review, and Buy or Sell Guide (2025)
Anthem Biosciences IPO Lists at 27% Premium – Should You Buy or Wait?
How would you like a 27% return immediately, not in months or years! This is what occurred when the Anthem Biosciences Limited launched its IPO on July 21, 2025. This listing surprised most of the investors and it performed well. But after the listing, is this stock still a buy? Let’s break it down.
Quick Overview of Anthem Biosciences IPO Listing
- IPO Price: ₹570 per share
- Listing Price: ₹723 per share
- Listing Premium: 27%
- Intra-Day High: ₹746.70
- Overall Subscription: 67 times
The IPO was over subscribed and that means that the investors were very big. On the opening day itself, Anthem Biosciences paid investors back with nearly 31 percent returns based on the IPO price
Why Did Anthem Biosciences Rally on Listing?
There are a number of factors which led to the excellent listing performance of Anthem Biosciences:
1.Strong Financials
- 30% revenue growth in FY25
- 37% EBITDA margins
- The biggest fermentation capacity in India (182 kL)
- More than 675 international customers in 44 nations
2.Business Model Strength
Anthem Biosciences is a major CRDMO (Contract Research, Development & Manufacturing Organization), that provides services to the highest quality of pharmaceutical and biotech companies around the world.It specializes in:
- Fermentation-based APIs
- Peptides
- RNA therapeutics
This has made it have some competitive advantage in the industry.
3.Strong Grey Market Premium (GMP)
The share of Anthem was doing well holding a 165-170 GMP before the listing, which meant investor confidence. This was forecasted to see a 29% listing gain- this was correct.
Listing Day Performance in Detail
| Details | Numbers |
|---|---|
| IPO Price | ₹570 |
| Listing Price (NSE) | ₹723.05 (+26.85%) |
| Listing Price (BSE) | ₹723.10 (+26.86%) |
| Intra-Day High | ₹746.70 (~31%) |
| Intra-Day Low | ₹710 |
| Subscription Overall | 67.24 times |
To BUY, HOLD or SELL Anthem Biosciences Stocks?
To Short-Term investors:
- Analysts are suggesting taking partial profits at present.
- Suggested stop-loss: ₹650.
- It can be considered to reinvest when price falls lower than 680.
In case you are a Long-Term Investor:
- Most analysts advise that the stock should be kept longer to earn more returns.
- Short-term target: ₹900.
- Long-term target: ₹1,000+.
The company has strong fundamentals and it holds a niche position, which is a sign of good things to come in the future that makes it an ideal company to create long-term wealth.
Important Factors to Watch
- Quarterly earnings updates (Q2 FY26)
- Expansion plans & new product launches
- The trends in global pharma district
- Competitive benchmarking (Divi, Syngene etc)
Expert Advice – Is it the Time to Invest?
- In case you received allotment: Look at partial profit booking.
- If you missed the IPO: Look for dips between ₹650–₹680 to enter.
- Long-term prospects are good on the basis of financials and growth trend.
Conclusion: Anthem Biosciences – A Strong Long-Term Bet?
The high initial performance of Anthem Biosciences speaks of its potential. It has a global client base with 27% listing premium and is all set to grow in the long term. New investors are better off waiting a minor correction to come.
In summary:
- Short-term traders: Book partial profits and trail stop-loss.
- Long-term investors: Hold or accumulate on dips.
- Missed IPO? monitor 650 to 680 area in view of new buying bid.
Also read : Top 5 ETFs vs. Mutual Funds – Where Will You Make More Money in 2025?
FAQs
Q1: How much was the offering price of Anthem Biosciences IPO?
A: 723 rs per share in both NSE and BSE.
Q2: Should I buy Anthem Biosciences shares now?
A: The analysts recommended that one should wait until there is a dip in order to buy to get long term profits.
Q3: What’s Anthem Biosciences’ business model?
A:It is a CRDMO specializing in: APIs, peptides and RNA therapeutics.
